Despite its success in multiple tumor types, immunotherapy remains poorly efficacious in brain malignancies. In this issue of Cell, Friebel et al. and Klemm et al. provide in-depth insights into the versatile nuances of immune cells in primary and metastatic brain tumors, granting the field with a rich framework to explore novel therapeutic avenues.
Copyright © 2020 Elsevier Inc. All rights reserved.